You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

40 Results
Drug
Other Name(s): Vesanoid®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Drug
Other Name(s): Thalomid®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Drug
Other Name(s): Inlyta®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Drug
Other Name(s): Mekinist®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025
Drug
Other Name(s): Giotrif®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Drug
Other Name(s): Alecensaro®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    aXitinib - For second or third line treatment of advanced renal cell carcinoma, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
aXitinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    trametinib - As monotherapy in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    AFAtinib - For first-line monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
AFAtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    alectinib - Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer, according to criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
alectinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative, Curative
Funding:
Exceptional Access Program
    tretinoin (ATRA)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
tretinoin (ATRA)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    tretinoin (ATRA)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
tretinoin (ATRA)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019

Pages